BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) announced that the board has formed a committee to identify a new chairman with relevant global experience to guide the company through the anticipated upcoming international Phase 3 trials and global commercialization.
Prof. Avner Rotman will continue to serve as chairman until a suitable replacement is identified.
The board also decided to voluntarily delist from the Tel Aviv Stock Exchange (TASE), while maintaining a continued listing on NASDAQ. The delisting process of BiondVax’s shares from trading on the TASE will take place by the end of 2017.
“BiondVax is proud to be an Israeli company,” CEO, Ron Babecoff, said in a statement. “Our technology was born in Israel, and we are building our new manufacturing facility in Israel. Nevertheless, a universal flu vaccine is a global product, which demands a global presence. The decision to consolidate trading on NASDAQ and to internationalize our board is an important step towards achieving our goals.”
